Analysts Point To Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Growth In The Future

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, ARQT falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Arcutis Biotherapeutics Inc is $1.14B. A total of 1.36 million shares were traded on the day, compared to an average of 2.26M shares.

In the most recent transaction, Welgus Howard G. sold 10,000 shares of ARQT for 9.26 per share on Oct 01 ’24. After the transaction, the Director now owns 181,944 company shares. In a previous transaction on Oct 02 ’24, Edwards Larry Todd sold 3,725 shares at 10.01 per share. ARQT shares that SVP Chief Commercial Officer owns now total 136,635.

Among the insiders who bought shares, Edwards Larry Todd acquired of 3,725 shares on Oct 02 ’24 at a per-share price of $10.01. In another insider transaction, Welgus Howard G. bought 10,000 shares at $9.26 per share on Oct 01 ’24.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ARQT has a high of $13.17 and a low of $1.76.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $1.60, while its Total Shareholder’s Equity was $297.68M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.57.

Most Popular

Related Posts